Sécurité des patients et analyse des causes racines

Auroy, Yves; Andreu, G.; Aullen, J.-P.; Benhamou, Dan; Caldani, C.; Canivet, N.; Lardemelle, C. de; Roure, François Desroys du; François, Anne Isabelle; Gruber, Michael; Sandid, Imad; Linget, C.; Loulière, Bertrice; Perrin, Mary; Rebibo, Danielle; Richomme, X.; Tinard, X.

doi:10.1016/j.tracli.2010.09.167

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…. ), le risque infectieux a été réduit par un facteur de plus de 1500 au cours des 20 dernières années alors que, dans le même temps, le risque d'accident ABO n'a été réduit que de moitié [1]. Selon des données récentes de l'Institut national de veille sanitaire, le risque résiduel moyen d'infection au cours de la période 2007-2009 serait en France de 1 sur 3 millions de dons pour HIV-1, de 1 sur 6 millions de dons pour HTLV, de 1 sur 10 millions de dons pour le virus de l'hépatite C (HCV) et de 1 sur 100 000 dons pour le virus de l'hépatite B (avant instauration du DGV pour ce dernier agent) [2].…”

Section: Introductionunclassified

Risques viraux émergents en transfusion sanguine

Pozzetto

Garraud

2011

Transfusion Clinique et Biologique

View full text Add to dashboard Cite

During the last 20 years, the safety of blood products increased dramatically with regard to the infectious risk and notably to that represented by retroviruses (HIV and HTLV) and hepatitis B and C viruses. The aim of this review is to identify the residual and emergent viral threats that could be responsible for the occurring of new contaminations in the receivers of blood products. Beside many other viruses (HHV-8, erythrovirus B19, hepatitis A and E viruses...), a special attention has been paid to emerging arbovirus diseases (West Nile virus infection, dengue, chikungunya) that threaten to occur in the French metropolitan area following the implantation in Europe of the mosquito Aedes albopictus, the main vector of dengue and chikungunya in temperate regions. Another blood-linked risk, notably in United Kingdom and France, is the prion agent responsible for the variant form of the Creutzfeldt-Jakob disease. The review is concluded by a brief overview of the measures aimed to control these emergences, including the exclusion of at-risk donors, the diagnostic tests able to detect a specific agent, the leukocyte reduction of labile blood products, and the physical or chemical treatments aiming the nonspecific inactivation of infectious agents potentially present in blood without impairing significantly the physiological properties of blood compounds. The ability to control prospectively the new viral risks linked to blood products is a challenge for the preservation of the confidence of both clinicians and receivers in the safety of blood transfusion.

show abstract

Section: Introductionunclassified